Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma
Abstract Glioblastoma is an aggressive and treatment-refractory primary brain tumor with limited therapeutic options and high recurrence. The molecular heterogeneity of glioblastoma poses a significant challenge to therapeutic development, as targeted therapies have mostly failed in small-scale clin...
Saved in:
| Main Authors: | Catherine Z. Beach, Christopher A. Febres-Aldana, Juan Luis Gomez Marti, Saeed Asiry, Tamika Wong, John A. Boockvar, Randy S. D’Amico, Romel Somwar, Monika A. Davare, Morana Vojnic |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-01076-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting the MDM2‐MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer
by: Sonia Valentini, et al.
Published: (2025-08-01) -
The Role of Nuclear Phosphoinositides in the p53-MDM2 Nexus
by: Jeong Hyo Lee, et al.
Published: (2025-07-01) -
Single-cell transcriptomics identifies PDGFRA+ progenitors orchestrating angiogenesis and periodontal tissue regeneration
by: Jianing Liu, et al.
Published: (2025-07-01) -
An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma
by: Joseph W. Jackson, et al.
Published: (2025-09-01) -
FIP1L1‐PDGFRA Positive Chronic Eosinophilic Leukemia Presenting With Vestibular Neuritis
by: Ahmad Abu‐Zahra, et al.
Published: (2025-06-01)